Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 2,456

Document Document Title
WO/2019/173642A1
The present disclosure describes compositions and methods for preventing and/or treating microbial infections of ciliated tissues, such as tissues of the trachea, lungs, and sinuses. A treatment composition comprises a CSA compound, a po...  
WO/2019/151838A1
Disclosed are a composition for clearing spheroids, a method for clearing spheroids using same, and a kit comprising same. The composition for clearing spheroids can clear the spheroids in a convenient and rapid manner and thus may be us...  
WO/2019/129913A1
The present invention relates to compounds of formula (I) derived from ursodeoxycholic acid, to processes for preparing them and to their use for the treatment of polycystic diseases, in particular autosomal dominant polycystic liver dis...  
WO/2019/129309A1
Provided is a preparation method for a dexamethasone intermediate, relating to the field of active pharmaceutical ingredient synthesis. Compound I in a buffer salt system undergoes a cyanide reaction to synthesize 17α-CN, and said produ...  
WO/2019/129176A1
The present invention provides a sarsasapogenin derivative and a preparation method and application thereof. The derivative has a structure as shown in formula I, and the definition of each substituent is as described in the specificatio...  
WO/2019/126741A1
Provided herein are compounds of Formula (I-I): and pharmaceutically acceptable salts thereof; wherein p, R1, R3a, R2a, R11a, R11b, R6a, and R6b are defined herein. Also provided herein are pharmaceutical compositions comprising a compou...  
WO/2019/119832A1
Provided are a compound for treating metabolic diseases having the structure as shown in formula (I) or formula (II), or a racemate, stereoisomer, geometric isomer, tautomer, solvate, hydrate, metabolite, pharmaceutically acceptable salt...  
WO/2019/114525A1
The present application discloses a plurality of novel derivatives of cucurbitacin B and cucurbitacin E, and salts thereof, and also discloses methods for preparing these novel derivatives. These new derivatives and their salts have comm...  
WO/2019/097434A1
The aspects of the present disclosure relates to novel lanosterol derivatives and novel 25-hydroxycholesterol derivatives including their pharmaceutically acceptable salts as well as methods of treatment and pharmaceutical compositions a...  
WO/2019/081586A1
The present invention relates to new and improved processes for the preparation of deoxycholic acid (DCA) and pharmaceutically acceptable salts thereof, as well as to DCA and pharmaceutically acceptable salts thereof, the carbon atoms of...  
WO/2019/039767A3
The present invention provides a composition for adjusting biological tissue size, and a method for adjusting the size of biological tissue using said composition. A composition for adjusting biological tissue according to the present in...  
WO/2019/039767A2
The present invention provides a composition for adjusting biological tissue size, and a method for adjusting the size of biological tissue using said composition. A composition for adjusting biological tissue according to the present in...  
WO/2018/224736A3
The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein Rl to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17P-HSD1 and in treatment or preve...  
WO/2018/232502A1
Polymeric transfection reagents for delivery of nucleic acids to cells, pharmaceutical compositions comprising same, and methods of preparing and using same are provided. A compound comprises polyethylenimine, a lipid selected from chole...  
WO/2018/237350A1
The present disclosure relates to methods and novel intermediates useful in the preparation of a compound of formula I or pharmaceutically acceptable salt, hydrate, solvate or amino acid, sulfate or glucuronide conjugate, or prodrug ther...  
WO/2018/223836A1
The present invention relates to a novel crystal form of a compound (I), a method for preparing same, and an application. Crystal form CS3, crystal form CS2, crystal form CS5, and crystal form CS8 of the compound (I) provided by the pres...  
WO/2018/224736A2
The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof (I) wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD1 and in treatment or ...  
WO/2018/213077A1
Provided herein are compounds, compositions, conjugates and methods for the treatment of diseases, and/or conditions such as, but not limited to, proliferative diseases. In certain embodiments, compounds, compositions, and conjugates are...  
WO/2018/201516A1
A compound and an application thereof for treatment of cataract. The structural formula of the compound is as shown in formula I. The compound of formula I, a prodrug thereof, or a pharmaceutically acceptable salt thereof, can be used to...  
WO/2018/187804A1
The present invention relates to processes for preparing compounds of Formula (I) and compounds of Formula (II) or a pharmaceutically acceptable salt or solvate thereof. These compounds and pharmaceutical compositions are useful as FXR o...  
WO/2018/175582A1
This disclosure relates to sporicidal compositions and uses thereof. The sporicidal compositions include one or more cationic steroidal antimicrobials (CSAs). The sporicidal compositions may be applied to an object to kill or deactivate ...  
WO/2018/089373A9
Described herein protein steroid conjugates whereby a glucocorticoid compound is conjugated to a binding agent which is preferably an antibody. These are useful, for example, for the target-specific delivery of glucocorticoids (GCs) to c...  
WO/2018/089373A3
Described herein protein steroid conjugates whereby a glucocorticoid compound is conjugated to a binding agent which is preferably an antibody. These are useful, for example, for the target-specific delivery of glucocorticoids (GCs) to c...  
WO/2018/103626A1
The present invention relates to the field of medicine, and particularly relates to a water-soluble allopregnenolone derivative, a pharmaceutical composition comprising the same, and use thereof in prevention or treatment of central nerv...  
WO/2018/102369A1
Methods and systems for making onapristone (ONA) using acidic hydrolysis and dehydration with sulfuric acid in an alcoholic solution are provided.  
WO/2018/089373A2
Described herein protein steroid conjugates that are useful, for example, for the target-specific delivery of glucocorticoids (GCs) to cells.  
WO/2018/068021A1
The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The s...  
WO/2018/064649A1
Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1A, R1B, n, R2A, R2B, R3, and R4 are as defined herein. Compounds of the present invention ...  
WO/2018/050815A1
The present invention relates to a compound of formula (I), in which R' represents a -(CRaRb)n-X-(CRcRd)m-[Y-(CReRf)o]t-NR9R10 group, and X and Y independently represent a -NR11- group, an –O- group or a divalent heterocyclic group com...  
WO/2018/050814A1
The present invention relates to a compound of formula (I), in which R' represents a –(CRaRb)n-X-(CRcRd)m-[Y-(CReRf)o]t-NR9R10 group, and X and Y independently represent a -NR11- group, an –O- group or a divalent heterocyclic group c...  
WO/2018/050099A1
Provided is a panaxdiol-type ginsenoside derivative having a structure as shown in formula I or formula II. Also provided is the use thereof in the preparation of a drug for preventing and treating atherosclerosis. The panaxdiol-type gin...  
WO/2018/031933A3
Provided herein are conjugated oligonucleotides that are characterized by efficient and specific tissue distribution.  
WO/2018/047090A1
The present invention pertains to a method of treating cancer or its relapse in mammals by employing platinum based compounds. More particularly, the present invention provides to enhance immunity in a mammal, using a compound of Formula...  
WO/2018/035079A1
A class of cyanosteroid compounds that efficiently inhibit ghrelin acylation by ghrelin O-acyltransferase. The compounds have a steroid scaffold with α,β-unsaturated ketone in the A ring position such an a-cyanoenone. Exemplary compoun...  
WO/2018/013613A1
Described herein are neuroactive steroids or a pharmaceutically acceptable salt thereof. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. Also provided are pharmaceutical compositions comprising a comp...  
WO/2017/211820A1
The present invention relates to new and improved processes for the preparation of deoxycholic acid (DCA) and pharmaceutically acceptable salts thereof, as well as to novel intermediates useful for the preparation of DCA and pharmaceutic...  
WO/2017/207648A1
The invention relates to a process for the preparation of obeticholic acid and derivatives thereof comprising: (a) olefination of a compound of formula (II) or a salt or solvate thereof to obtain a compound of formula (III) or a salt or ...  
WO/2017/199033A1
The invention relates to compounds of general formula (I): wherein: R1,R2, R3, R4, R5, R6 and Y are as defined herein. The compounds are intermediates in the synthesis of synthetic bile acids which are useful in the treatment of conditio...  
WO/2017/199039A1
The invention relates to a process for preparing a compound of general formula (Ia): wherein R2, Y, R4 and R5 are as defined herein. The invention also relates to certain compounds per se. The compounds are intermediates in the synthesis...  
WO/2017/186135A1
Disclosed in the present invention are a compound and an application thereof for the treatment of cataracts. The structural formula of the compound is shown in formula I. The compound shown in formula I, a prodrug thereof, or a pharmaceu...  
WO/2017/156418A1
This disclosure relates to dermal treatment compositions, such as dermal fillers and tissue glues, and injectable compositions that incorporate one or more cationic steroidal antimicrobials (CSAs). The CSAs are incorporated into the derm...  
WO/2017/147159A1
The present invention provides compounds of Formula (I) or Formula (II), pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.  
WO/2017/146440A1
The present invention relates to co-crystals of androstenone and vanillin, a method for preparing the same and a use of the same. The co-crystals of androstenone and vanillin of the present invention have a rigid lattice structure so as ...  
WO/2017/106957A8
This invention provides lipid-linked prodrugs having structures as set out herein. Uses of such lipid-linked prodrug compounds for treatment of various indications, and methods for making and using lipid-linked prodrugs are also provided.  
WO/2017/112904A1
The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The s...  
WO/2017/106957A1
This invention provides lipid-linked prodrugs having structures as set out herein. Uses of such lipid-linked prodrug compounds for treatment of various indications, and methods for making and using lipid-linked prodrugs are also provided.  
WO/2017/112909A1
The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The s...  
WO/2017/112902A1
The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The s...  
WO/2017/106214A1
Amorphous forms of onapristone and methods of making such amorphous forms are provided. Amorphous forms can be characterized by their X-ray powder diffraction patterns and other properties.  
WO/2017/083794A1
Polyethylene glycol (PEG)-conjugated glucocorticoid prodrugs, methods of preparation, and use for the treatment of diseases and disorders are disclosed. In particular, PEG-conjugated dexamethasone compounds and methods of using them for ...  

Matches 1 - 50 out of 2,456